<div id="readability-page-1"><div><ul> <li>Guardant Health (NasdaqGS:GH) partnered with actor and cancer advocate Patrick Dempsey to raise awareness of colorectal cancer screening and its FDA approved Shield blood test.</li> <li>The company also agreed to acquire MetaSight Diagnostics, adding next generation liquid biopsy technology aimed at early disease detection.</li> </ul> <p>Guardant Health, a precision oncology company listed on NasdaqGS:GH, focuses on blood based tests for cancer screening, treatment selection and disease monitoring. The collaboration with Patrick Dempsey brings additional attention to colorectal cancer screening options, including Guardant Health’s Shield blood test. Early detection remains a major health priority, and higher public awareness can be an important ingredient for test adoption over time.</p> <p>The MetaSight Diagnostics acquisition adds to Guardant Health’s toolkit for earlier and more refined detection of disease using liquid biopsy approaches. As the company integrates MetaSight’s technology and research pipeline, investors may monitor how Guardant Health positions its expanded testing portfolio across screening, diagnostics and treatment decision support in the coming years.</p> <p>Stay updated on the most important news stories for Guardant Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Guardant Health.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA0"/><figcaption>NasdaqGS:GH Earnings &amp; Revenue Growth as at Mar 2026</figcaption></figure> <p>📰 Beyond the headline: 3 risks and 3 things going right for Guardant Health that every investor should see.</p> <h3>Quick Assessment</h3> <ul> <li><strong>✅ Price vs Analyst Target</strong>: At US$93.30 versus a consensus target of US$132.57, shares sit about 30% below where analysts as a group think the price could reasonably be.</li> <li><strong>✅ Simply Wall St Valuation</strong>: The stock is assessed as undervalued, trading roughly 37.5% below the estimated fair value.</li> <li><strong>❌ Recent Momentum</strong>: The 30 day return of about 18.2% decline shows the market has been cautious in the short term.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Guardant Health. Head to Simply Wall St's company report for the latest analysis of Guardant Health's fair value.</p> <h3>Key Considerations</h3> <ul> <li>📊 The Patrick Dempsey partnership and MetaSight deal both push Guardant further into early detection and screening, which sit at the core of its blood based testing focus.</li> <li>📊 Keep an eye on adoption of the Shield blood test, integration progress for MetaSight's liquid biopsy technology and how these feed into revenue and margin trends.</li> <li>⚠️ The company is currently loss making with negative shareholders' equity and has been flagged for profitability risks, so funding needs and balance sheet strength remain key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the complete Guardant Health analysis. Alternatively, you can visit the community page for Guardant Health to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>Guardant Health has partnered with actor Patrick Dempsey to promote colorectal cancer screening and its Shield blood test. The company is also acquiring MetaSight Diagnostics to enhance its liquid biopsy technology for early disease detection. This collaboration aims to increase awareness and adoption of cancer screening. Investors should monitor the integration of MetaSight's technology and the performance of the Shield test, as Guardant Health faces profitability risks and is currently loss-making. The stock is considered undervalued, trading below analyst targets.</p>

Simplywall

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Healthcare Providers

SPDR S&P Biotech

iShares Genomics Immunology and Healthcare ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Medical Devices

Guardant Health

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Guardant Health Targets Early Detection Growth With New Partner And Acquisition